マーケットレポート詳細
バイオシミラーの世界市場：医薬品クラス別、適応症別2028年予測
Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年6月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文298ページになります。
- 商品コード：MAM3279
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
バイオシミラーの世界市場規模は2023年で294億ドルに達し、2028年までに669億ドルへと拡大、その間の市場の平均年成長率は17.8%で推移することが見込まれています。
レポートはバイオシミラーの世界市場について2028年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（医薬品クラス別市場、適応症別市場、等）を中心に構成されています。また競合状況、主要企業情報（25社）、市場ダイナミクス、バリューチェーン分析などの分析も加味し、バイオシミラー市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆バイオシミラーの世界市場予測2021-2028年
・市場規模(US$)
◆医薬品クラス別、市場-2028年
モノクローナル抗体
・インフリキシマブ
・リツキシマブ
・トラスツズマブ
・アダリムマブ
・その他モノクローナル抗体
顆粒球コロニー刺激因子
インスリン
エリスロポエチン
組換えヒト成長ホルモン
エタネルセプト
ホリトロピン
テリパラチド
インターフェロン
抗凝血剤
その他医薬品クラス
※(市場規模US$)
◆適応症別、市場-2028年
・腫瘍学
・炎症性および自己免疫疾患
・慢性疾患
・血液疾患
・成長ホルモン欠乏症
・感染症
・その他適応症
※(市場規模US$)
◆主要国地域別市場-2028年
欧州
・ドイツ、英国、フランス、イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、韓国、インド、オーストラリア
・その他アジア太平洋
北米
・米国、カナダ
中南米
中東アフリカ
※国地域別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（促進要因、障壁、機会、課題）
・バリューチェーン分析
・エコシステム市場マップ
・業界構造分析（ファイブフォース分析）
・規制の状況
・主要なステークホルダーと購買基準
・価格分析
・競合状況
・市場シェア分析
◆バイオシミラーの主要企業プロフィール動向
・NOVARTIS AG
・PFIZER INC.
・AMGEN INC.
・DR. REDDY’S LABORATORIES LTD.
・ELI LILLY AND COMPANY
・TEVA PHARMACEUTICAL INDUSTRIES
・FRESENIUS KABI AG
・STADA ARZNEIMITTEL AG
・BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・F. HOFFMANN-LA ROCHE LTD
・CELLTRION HEALTHCARE CO., LTD.
・SAMSUNG BIOLOGICS
・COHERUS BIOSCIENCES
・BIOCON
・AMEGA BIOTECH
・APOTEX INC.
・BIOCAD
・MABXIENCE
・PROBIOMED
・協和キリン富士フイルムバイオロジクス株式会社
・INTAS PHARMACEUTICALS LTD.
・RELIANCE LIFE SCIENCES
・KASHIV BIOSCIENCES, LLC
・USV PRIVATE LIMITED
・AMNEAL PHARMACEUTICALS, INC.
（その他企業）
・FORMYCON AG
・POLPHARMA BIOLOGICS GROUP
・AMPHASTAR PHARMACEUTICALS, INC.
・ALVOTECH
・UCB SA
（全298頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
・ FIGURE 1 BIOSIMILARS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS 35
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
・ FIGURE 3 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
・ FIGURE 4 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
・ FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
・ FIGURE 6 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE ANALYSIS AND SEGMENTAL ANALYSIS, 2022
・ FIGURE 7 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE FOR DRUG CLASS & INDICATION, 2022
2.2.1 INSIGHTS FROM PRIMARIES
・ FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
・ FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
・ FIGURE 10 BIOSIMILARS MARKET: CAGR PROJECTIONS, 2023–2028
・ FIGURE 11 BIOSIMILARS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 BIOSIMILARS MARKET: RECESSION IMPACT ANALYSIS
・ TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH)
・ TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION)
・ TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
・ FIGURE 13 BIOSIMILARS MARKET, BY DRUG CLASS, 2023 VS. 2028 (USD MILLION)
・ FIGURE 14 BIOSIMILARS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
・ FIGURE 15 BIOSIMILARS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 BIOSIMILARS MARKET OVERVIEW
・ FIGURE 16 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS AND COUNTRY (2022)
・ FIGURE 17 MONOCLONAL ANTIBODIES AND US TO DOMINATE NORTH AMERICAN MARKET
4.3 BIOSIMILARS MARKET: GEOGRAPHICAL SNAPSHOT
・ FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 19 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
・ TABLE 4 BIOSIMILARS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 INCREASING DEMAND FOR BIOSIMILARS
5.2.1.2 LAUNCH OF NOVEL BIOSIMILARS
・ FIGURE 20 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015 TO 2022
5.2.1.3 RISING GERIATRIC POPULATION AND CHRONIC DISEASE INCIDENCE
・ FIGURE 21 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
・ FIGURE 22 ESTIMATED NUMBER OF NEW CANCER CASES FROM 2020 TO 2030
・ FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
5.2.1.4 ABBREVIATED REGULATORY APPROVAL PROCESS AND INTERCHANGEABILITY
・ TABLE 5 APPROVED BIOSIMILARS WITH INTERCHANGEABLE DESIGNATION
・ FIGURE 24 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
5.2.2 RESTRAINTS
5.2.2.1 COMPLEXITIES IN MANUFACTURING
・ TABLE 6 COMPARISON OF DRUG DEVELOPMENT PROCESSES, BY TYPE
5.2.3 OPPORTUNITIES
5.2.3.1 EMERGING MARKETS
5.2.3.2 PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS AND RESEARCH INTO NEW INDICATIONS
・ TABLE 7 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY
5.2.4 CHALLENGES
5.2.4.1 HIGH COMPETITION AND REGULATORY CHALLENGES
5.3 VALUE CHAIN ANALYSIS
・ FIGURE 25 VALUE CHAIN ANALYSIS FOR BIOSIMILARS
5.4 ECOSYSTEM MARKET MAP
・ FIGURE 26 ECOSYSTEM MARKET MAP FOR BIOSIMILARS
5.5 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 8 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS 71
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
・ TABLE 9 BIOSIMILARS MARKET: REGULATORY LANDSCAPE
・ TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
・ TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 14 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 KEY CONFERENCES AND EVENTS, 2023
・ TABLE 15 BIOSIMILARS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
・ FIGURE 27 KEY STAKEHOLDERS IN BUYING PROCESS
・ FIGURE 28 INFLUENCE OF END USERS ON BUYING PROCESS
5.9 PATENT ANALYSIS
5.10 PIPELINE ANALYSIS
5.11 PRICING ANALYSIS
・ TABLE 16 BIOSIMILAR PRICE, BY INDICATION AND REGION
5.12 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 BIOSIMILARS MARKET, BY DRUG CLASS
6.1 INTRODUCTION
・ TABLE 17 BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
6.2 MONOCLONAL ANTIBODIES
・ TABLE 18 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 19 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 20 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 21 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 22 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1 INFLIXIMAB
6.2.1.1 INFLIXIMAB TO DOMINATE MABS MARKET
・ TABLE 23 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 24 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 25 EUROPE: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 26 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 RITUXIMAB
6.2.2.1 RISING INCIDENCES OF AUTOIMMUNE DISEASES AND CANCER TO BOOST MARKET GROWTH
・ TABLE 27 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 28 NORTH AMERICA: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 29 EUROPE: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 30 ASIA PACIFIC: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.3 TRASTUZUMAB
6.2.3.1 INCREASING BREAST CANCER PREVALENCE TO DRIVE MARKET GROWTH
・ TABLE 31 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 32 NORTH AMERICA: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 33 EUROPE: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 34 ASIA PACIFIC: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.4 ADALIMUMAB
6.2.4.1 LOSS OF PATENT EXCLUSIVITY TO DRIVE RESEARCH
・ TABLE 35 FDA APPROVAL AND EU LAUNCH STATUS OF BIOSIMILARS TO HUMIRA
・ TABLE 36 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 37 NORTH AMERICA: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 38 EUROPE: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 39 ASIA PACIFIC: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.5 OTHER MONOCLONAL ANTIBODIES 98
・ TABLE 40 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 41 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 42 EUROPE: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 43 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 GRANULOCYTE COLONY-STIMULATING FACTOR
6.3.1 LAUNCH OF BIOSIMILARS TO PROMOTE MARKET GROWTH
・ TABLE 44 LIST OF APPROVED BIOSIMILARS FOR G-CSF
・ TABLE 45 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 46 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 47 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 48 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 INSULIN
6.4.1 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET
・ TABLE 49 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 50 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 51 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 52 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 ERYTHROPOIETIN
6.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH
・ TABLE 53 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
・ TABLE 54 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 55 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 56 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 57 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 RECOMBINANT HUMAN GROWTH HORMONE
6.6.1 INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS TO PROPEL MARKET
・ TABLE 58 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 59 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 60 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 61 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 ETANERCEPT 112
6.7.1 APAC TO WITNESS HIGHEST GROWTH IN ETANERCEPT MARKET
・ TABLE 62 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 63 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 64 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 65 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021–2028 (USD MILLION)
6.8 FOLLITROPIN 114
6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET
・ TABLE 66 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 67 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 68 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 69 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021–2028 (USD MILLION)
6.9 TERIPARATIDE
6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND
・ TABLE 70 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 71 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 72 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 73 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021–2028 (USD MILLION)
6.10 INTERFERONS 118
6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
・ TABLE 74 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 75 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
6.11 ANTICOAGULANTS
6.11.1 WIDE RANGE OF APPLICATIONS TO DRIVE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
・ TABLE 76 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 77 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 78 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 79 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021–2028 (USD MILLION)
6.12 OTHER DRUG CLASSES
・ TABLE 80 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 81 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2021–2028 (USD MILLION)
7 BIOSIMILARS MARKET, BY INDICATION
7.1 INTRODUCTION
・ TABLE 82 BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS IN ONCOLOGY TO DRIVE MARKET
・ TABLE 83 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 84 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 85 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 86 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO INCREASE DISEASE INCIDENCE
・ TABLE 87 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 88 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 89 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 90 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 CHRONIC DISEASES
7.4.1 HIGH BURDEN OF CVD AND DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
・ TABLE 91 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 92 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 93 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 94 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 BLOOD DISORDERS
7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND
・ TABLE 95 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 96 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 97 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 98 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 GROWTH HORMONE DEFICIENCY
7.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT TO SUPPORT MARKET GROWTH
・ TABLE 99 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 100 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 101 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 102 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION)
7.7 INFECTIOUS DISEASES
7.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC
・ TABLE 103 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 104 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.8 OTHER INDICATIONS
・ TABLE 105 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 106 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 107 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 108 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 BIOSIMILARS MARKET, BY REGION
8.1 INTRODUCTION
・ TABLE 109 BIOSIMILARS MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2 EUROPE
・ TABLE 110 EUROPE: LIST OF APPROVED BIOSIMILARS
・ FIGURE 29 EUROPE: BIOSIMILARS MARKET SNAPSHOT
・ TABLE 111 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 112 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 113 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 114 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.1 GERMANY
8.2.1.1 GERMANY TO DOMINATE EUROPEAN BIOSIMILARS MARKET
・ TABLE 115 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 116 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 117 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.2 UK
8.2.2.1 INCREASING ADOPTION OF BIOSIMILARS TO BOOST MARKET
・ TABLE 118 UK: LIST OF APPROVED BIOSIMILARS
・ TABLE 119 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 120 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 121 UK: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.3 FRANCE
8.2.3.1 RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH
・ TABLE 122 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 123 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 124 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.4 ITALY
8.2.4.1 FAVORABLE GOVERNMENT POLICIES TO PROPEL ADOPTION OF BIOSIMILARS
・ TABLE 125 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 126 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 127 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.5 SPAIN
8.2.5.1 FAVORABLE PATIENT INCENTIVES TO PROMOTE BIOSIMILAR USE
・ TABLE 128 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 129 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 130 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.6 REST OF EUROPE
・ TABLE 131 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 132 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 133 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2.7 EUROPE: RECESSION IMPACT
8.3 ASIA PACIFIC
・ FIGURE 30 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
・ TABLE 134 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 135 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 136 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 137 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.1 CHINA
8.3.1.1 CHINA TO REGISTER HIGHEST GROWTH IN ASIA PACIFIC MARKET
・ TABLE 138 BIOSIMILARS APPROVED IN CHINA
・ TABLE 139 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 140 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 141 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.2 SOUTH KOREA
8.3.2.1 FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT GROWTH
・ TABLE 142 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS
・ TABLE 143 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 144 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 145 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.3 INDIA
8.3.3.1 INCREASING BIOSIMILAR LAUNCHES AND APPROVALS TO SUPPORT MARKET GROWTH
・ TABLE 146 BIOSIMILARS APPROVED AND MARKETED IN INDIA
・ TABLE 147 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 148 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 149 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.4 JAPAN
8.3.4.1 LARGE GERIATRIC POPULATION TO DRIVE MARKET GROWTH
・ TABLE 150 JAPAN: LIST OF APPROVED BIOSIMILARS
・ TABLE 151 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 152 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 153 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.5 AUSTRALIA
8.3.5.1 FAVORABLE REGULATORY CHANGES AND INCREASING DISEASE INCIDENCE TO PROPEL GROWTH
・ TABLE 154 AUSTRALIA: LIST OF APPROVED BIOSIMILARS
・ TABLE 155 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 156 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 157 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.6 REST OF ASIA PACIFIC
・ TABLE 158 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS
・ TABLE 159 MALAYSIA: LIST OF APPROVED BIOSIMILARS
・ TABLE 160 SINGAPORE: LIST OF APPROVED BIOSIMILARS
・ TABLE 161 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 162 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 198
・ TABLE 163 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.3.7 ASIA PACIFIC: RECESSION IMPACT
8.4 NORTH AMERICA
・ TABLE 164 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 165 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 166 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 167 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.4.1 US
8.4.1.1 US TO DOMINATE NORTH AMERICAN BIOSIMILARS MARKET
・ TABLE 168 US: LIST OF APPROVED BIOSIMILARS
・ TABLE 169 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 170 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 171 US: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.4.2 CANADA
8.4.2.1 FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET
・ TABLE 172 CANADA: LIST OF APPROVED BIOSIMILARS
・ TABLE 173 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 174 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 175 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.4.3 NORTH AMERICA: RECESSION IMPACT
8.5 LATIN AMERICA
8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET
・ TABLE 176 LATIN AMERICA: LIST OF APPROVED BIOSIMILARS
・ TABLE 177 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 178 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 179 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.5.2 LATIN AMERICA: RECESSION IMPACT
8.6 MIDDLE EAST AND AFRICA
8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
・ TABLE 180 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
・ TABLE 181 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 182 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 STRATEGIES ADOPTED BY KEY PLAYERS
・ FIGURE 31 BIOSIMILARS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
9.3 REVENUE SHARE ANALYSIS
・ FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2023
9.4 MARKET SHARE ANALYSIS
・ FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
・ TABLE 183 BIOSIMILARS MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT, 2022
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
・ FIGURE 34 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2022
9.6 COMPETITIVE BENCHMARKING OF TOP 30 PLAYERS
9.6.1 COMPANY FOOTPRINT ANALYSIS (30 COMPANIES)
・ TABLE 184 BIOSIMILARS MARKET: COMPANY FOOTPRINT ANALYSIS
9.6.2 PRODUCT FOOTPRINT ANALYSIS (30 COMPANIES)
・ TABLE 185 BIOSIMILARS MARKET: PRODUCT FOOTPRINT ANALYSIS
9.6.3 REGIONAL FOOTPRINT ANALYSIS (30 COMPANIES)
・ TABLE 186 BIOSIMILARS MARKET: REGIONAL FOOTPRINT ANALYSIS
9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
9.7.1 PROGRESSIVE COMPANIES
9.7.2 STARTING BLOCKS
9.7.3 RESPONSIVE COMPANIES
9.7.4 DYNAMIC COMPANIES
・ FIGURE 35 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
・ TABLE 187 BIOSIMILARS MARKET: DETAILED LIST OF KEY START-UPS/SMES
・ TABLE 188 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
9.9 COMPETITIVE SCENARIO AND TRENDS
9.9.1 PRODUCT LAUNCHES & APPROVALS
・ TABLE 189 BIOSIMILARS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
9.9.2 DEALS
・ TABLE 190 BIOSIMILARS MARKET: DEALS, JANUARY 2020–APRIL 2023
9.9.3 OTHER DEVELOPMENTS
・ TABLE 191 BIOSIMILARS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
10 COMPANY PROFILES
10.1 KEY MARKET PLAYERS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS))*
10.1.1 NOVARTIS AG
・ TABLE 192 NOVARTIS AG: BUSINESS OVERVIEW
・ FIGURE 36 NOVARTIS AG: COMPANY SNAPSHOT (2022)
10.1.2 PFIZER INC.
・ TABLE 193 PFIZER INC.: BUSINESS OVERVIEW
・ FIGURE 37 PFIZER INC.: COMPANY SNAPSHOT (2022)
10.1.3 AMGEN INC.
・ TABLE 194 AMGEN INC.: BUSINESS OVERVIEW
・ FIGURE 38 AMGEN INC.: COMPANY SNAPSHOT (2022)
10.1.4 DR. REDDY’S LABORATORIES LTD.
・ TABLE 195 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
・ FIGURE 39 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2022)
10.1.5 ELI LILLY AND COMPANY
・ TABLE 196 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
・ FIGURE 40 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
10.1.6 TEVA PHARMACEUTICAL INDUSTRIES
・ TABLE 197 TEVA PHARMACEUTICAL INDUSTRIES: BUSINESS OVERVIEW
・ FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2022)
10.1.7 FRESENIUS KABI AG
・ TABLE 198 FRESENIUS KABI AG: BUSINESS OVERVIEW
・ FIGURE 42 FRESENIUS KABI AG: COMPANY SNAPSHOT (2022)
10.1.8 STADA ARZNEIMITTEL AG
・ TABLE 199 STADA ARZNEIMITTEL AG: BUSINESS OVERVIEW
・ FIGURE 43 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2022)
10.1.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・ TABLE 200 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
・ FIGURE 44 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
10.1.10 F. HOFFMANN-LA ROCHE LTD
・ TABLE 201 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
・ FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
10.1.11 CELLTRION HEALTHCARE CO., LTD.
・ TABLE 202 CELLTRION HEALTHCARE CO., LTD.: BUSINESS OVERVIEW
・ FIGURE 46 CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT (2022)
10.1.12 SAMSUNG BIOLOGICS
・ TABLE 203 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
・ FIGURE 47 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
10.1.13 COHERUS BIOSCIENCES
・ TABLE 204 COHERUS BIOSCIENCES: BUSINESS OVERVIEW
・ FIGURE 48 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2022)
10.1.14 BIOCON
・ TABLE 205 BIOCON: BUSINESS OVERVIEW
・ FIGURE 49 BIOCON: COMPANY SNAPSHOT (2022)
10.1.15 AMEGA BIOTECH
・ TABLE 206 AMEGA BIOTECH: BUSINESS OVERVIEW
10.1.16 APOTEX INC.
・ TABLE 207 APOTEX INC.: BUSINESS OVERVIEW
10.1.17 BIOCAD
・ TABLE 208 BIOCAD: BUSINESS OVERVIEW
10.1.18 MABXIENCE
・ TABLE 209 MABXIENCE: BUSINESS OVERVIEW 284
10.1.19 PROBIOMED
・ TABLE 210 PROBIOMED: BUSINESS OVERVIEW 286
10.1.20 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
・ TABLE 211 FUJIFILM KYOVA KIRIN BIOLOGICS CO., LTD.: BUSINESS OVERVIEW
10.1.21 INTAS PHARMACEUTICALS LTD. 288
・ TABLE 212 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.1.22 RELIANCE LIFE SCIENCES
・ TABLE 213 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
10.1.23 KASHIV BIOSCIENCES, LLC
・ TABLE 214 KASHIV BIOSCIENCES, LLC: BUSINESS OVERVIEW
10.1.24 USV PRIVATE LIMITED
・ TABLE 215 USV PRIVATE LIMITED: BUSINESS OVERVIEW
10.1.25 AMNEAL PHARMACEUTICALS, INC. 295
・ TABLE 216 AMNEAL PHARMACEUTICALS INC.: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 FORMYCON AG
10.2.2 POLPHARMA BIOLOGICS GROUP
10.2.3 AMPHASTAR PHARMACEUTICALS, INC.
10.2.4 ALVOTECH
10.2.5 UCB SA
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS) MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.